Sundhedsstyrelsens nye retningslinier - DSOG

3
Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, et al. European guidelines for quality
assurance in cervical cancer screening. Second Edition. 2008
4
Moriarty AT, Clayton AC, Zaleski S, Henry MR, Schwartz MR, Eversole GM et al.Unsatisfactory
Reporting Rates. Arch Pathol Lab Med 2009 Dec;133(12):1912-6.
5
Wilbur DC, Black-Schaffer WS, Luff RD, Abraham KP, Kemper C, Molina JT et al. The Becton
Dickinson FocalPoint GS Imaging System Clinical Trials Demonstrate Significantly Improved
Sensitivity for the Detection of Important Cervical Lesions Am J Clin Pathol 2009;132:767-75.
6
Quality assurance manual – Cervical Cancer Screening Programme. Kreftregisteret, Institute of
population-based cancer research .Oslo 2005.
http://www.kreftregisteret.no/Global/Kvalitetsmanualer/kvalitetsmanual_livmorhals.pdf april 2011
7
Claeys P, Broutet N, Ullrich A. WHO, Comprehensive Cervical Cancer Control. A guide to essential
practice. 2006.
http://www.who.int/reproductivehealth/publications/cancers/9241547006/en/index.html april 2011
8
Solomon D, Nayar R. The Bethsda System for Reporting Cervical Cytology. Definitions, Criteria,
and Explanatory Notes. 2 nd ed. Springer Verlag, New York, 2004
9
Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M et al. Forum Group Members;
Bethesda 2001 Workshop. The 2001 Bethesda System: terminology for reporting results of cervical
cytology. JAMA 2002 Apr 24;287(16):2114-9.
10
Mitchell HS. Longitudinal Analysis of Histological High-Grade Disease after Negative Cervical
Cytology According to Endocervical Status. Cancer Cytopath 2001;93:237-40.
11
Bos AB, van Ballegooijen M, Elske van den Akker-van Marle M, Hanselaar AG, van Oortmarssen
GJ, Habbema JD. Endocervical status is not predictive of the incidence of cervical cancer in the
years after negative smears. Am J Clin Pathol 2001;115:851-5.
12
Tacken MA, Braspenning JC, Mulder J, Hermens RP, Nelen WL, de Bakker DH et al. Loss to follow-up
of cervical smears without endocervical columnar cells is not disturbing. Eur J Gynaecol
Oncol. 2006;27:42-6.
13
Siebers A, Leeuw H, Verbeek A L M, Hanselaar A G J M. Prevalence of squamous abnormalities
with a recent smear without endocervical cells is lower as compared to women with endocervikal
cells. Cytopathology 2003;14:58.
14
Selvaggi S M, Guidos B J. Endocervical component is it a determinant of specimen adequacy? Diagn.
Cytopathology 2002;261:53-5.
15
Lorincz, A. T. 1996. Hybrid Capture method for detection of human papillomavirus DNA in clinical
specimens: a tool for clinical management of equivocal Pap smears and for population screening.
J Obstet Gynaecol Res 22:629-36.
Screening for livmoderhalskkræft. Anbefalinger 2011
86